Tabes Dorsalis diagnostic study of choice: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 9: Line 9:


=== Study of choice: ===
=== Study of choice: ===
* [[FTA-ABS|Fluorescent treponemal antibody absorbed (FTA-ABS) tests]] are the gold standard test for the diagnosis of tabes dorsalis.<ref name="pmid20846810">{{cite journal| author=Lin LR, Fu ZG, Dan B, Jing GJ, Tong ML, Chen DT et al.| title=Development of a colloidal gold-immunochromatography assay to detect immunoglobulin G antibodies to Treponema pallidum with TPN17 and TPN47. | journal=Diagn Microbiol Infect Dis | year= 2010 | volume= 68 | issue= 3 | pages= 193-200 | pmid=20846810 | doi=10.1016/j.diagmicrobio.2010.06.019 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20846810  }} </ref>
* The first step laboratory test when there is a clinical suspicious toward tabes dorsalis is a  [[Venereal Disease Research Laboratory test|venereal disease research laboratory test (VDRL)]]  or [[Rapid plasma reagent|rapid plasma reagin (RPR)]].
* The [[FTA-ABS|fluorescent treponemal antibody absorbed (FTA-ABS) test]] should be performed when:.
* [[FTA-ABS|Fluorescent treponemal antibody absorbed (FTA-ABS) test]] is the gold standard test for the diagnosis of tabes dorsalis.<ref name="pmid20846810">{{cite journal| author=Lin LR, Fu ZG, Dan B, Jing GJ, Tong ML, Chen DT et al.| title=Development of a colloidal gold-immunochromatography assay to detect immunoglobulin G antibodies to Treponema pallidum with TPN17 and TPN47. | journal=Diagn Microbiol Infect Dis | year= 2010 | volume= 68 | issue= 3 | pages= 193-200 | pmid=20846810 | doi=10.1016/j.diagmicrobio.2010.06.019 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20846810  }} </ref>
** A positive [[Venereal Disease Research Laboratory test|Venereal Disease Research Laboratory test (VDRL)]] or [[Rapid plasma reagent|rapid plasma reagin (RPR)]] is detected in the patient.
* The [[FTA-ABS|fluorescent treponemal antibody absorbed (FTA-ABS) test]] should be performed when:
** A positive [[Venereal Disease Research Laboratory test|venereal disease research laboratory test (VDRL)]] or [[Rapid plasma reagent|rapid plasma reagin (RPR)]] is detected in the patient.


==== The comparison table for diagnostic studies of choice for [disease name] ====
==== The comparison table for diagnostic studies of choice for tabes dorsalis ====
{|
{|
|- style="background: #4479BA; color: #FFFFFF; text-align: center;"
|- style="background: #4479BA; color: #FFFFFF; text-align: center;"
Line 21: Line 22:
|-
|-
! style="background: #696969; color: #FFFFFF; text-align: center;" |FTA-ABS
! style="background: #696969; color: #FFFFFF; text-align: center;" |FTA-ABS
| style="background: #DCDCDC; padding: 5px; text-align: center;" |84% for detecting primary syphilis infection and almost 100% sensitivity for detecting syphilis infection in other stages<ref name="pmid15335137" />
| style="background: #DCDCDC; padding: 5px; text-align: center;" |
* 84% for detecting primary [[syphilis]] infection
* 100% sensitivity for detecting [[syphilis]] infection in secondary and tertiary stages<ref name="pmid15335137" />
| style="background: #DCDCDC; padding: 5px; text-align: center;" |96%<ref name="pmid15335137">{{cite journal| author=Calonge N, U.S. Preventive Services Task Force| title=Screening for syphilis infection: recommendation statement. | journal=Ann Fam Med | year= 2004 | volume= 2 | issue= 4 | pages= 362-5 | pmid=15335137 | doi= | pmc=1466700 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15335137  }} </ref>
| style="background: #DCDCDC; padding: 5px; text-align: center;" |96%<ref name="pmid15335137">{{cite journal| author=Calonge N, U.S. Preventive Services Task Force| title=Screening for syphilis infection: recommendation statement. | journal=Ann Fam Med | year= 2004 | volume= 2 | issue= 4 | pages= 362-5 | pmid=15335137 | doi= | pmc=1466700 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15335137  }} </ref>
|-
|-
! style="background: #696969; color: #FFFFFF; text-align: center;" |VDRL/RPR
! style="background: #696969; color: #FFFFFF; text-align: center;" |VDRL/RPR
| style="background: #DCDCDC; padding: 5px; text-align: center;" |78% to 86% for detecting primary syphilis infection, 100% for detecting secondary syphilis infection, and 95% to 98% for detecting latent syphilis infection<ref name="pmid15335137" />
| style="background: #DCDCDC; padding: 5px; text-align: center;" |
* 78% to 86% for detecting primary syphilis infection
* 100% for detecting secondary syphilis infection, and 95% to 98% for detecting latent syphilis infection<ref name="pmid15335137" />
| style="background: #DCDCDC; padding: 5px; text-align: center;" |85% to 99%<ref name="pmid15335137" />
| style="background: #DCDCDC; padding: 5px; text-align: center;" |85% to 99%<ref name="pmid15335137" />
|}
|}


==References==
==References==

Revision as of 19:31, 1 March 2018

Tabes Dorsalis Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Tabes Dorsalis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications, and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Tabes Dorsalis diagnostic study of choice On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Tabes Dorsalis diagnostic study of choice

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Tabes Dorsalis diagnostic study of choice

CDC on Tabes Dorsalis diagnostic study of choice

Tabes Dorsalis diagnostic study of choice in the news

Blogs on Tabes Dorsalis diagnostic study of choice

Directions to Hospitals Treating Tabes Dorsalis

Risk calculators and risk factors for Tabes Dorsalis diagnostic study of choice

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

Diagnostic Study of Choice

Template statements

Study of choice:

The comparison table for diagnostic studies of choice for tabes dorsalis

Sensitivity Specificity
FTA-ABS
  • 84% for detecting primary syphilis infection
  • 100% sensitivity for detecting syphilis infection in secondary and tertiary stages[2]
96%[2]
VDRL/RPR
  • 78% to 86% for detecting primary syphilis infection
  • 100% for detecting secondary syphilis infection, and 95% to 98% for detecting latent syphilis infection[2]
85% to 99%[2]

References

  1. Lin LR, Fu ZG, Dan B, Jing GJ, Tong ML, Chen DT; et al. (2010). "Development of a colloidal gold-immunochromatography assay to detect immunoglobulin G antibodies to Treponema pallidum with TPN17 and TPN47". Diagn Microbiol Infect Dis. 68 (3): 193–200. doi:10.1016/j.diagmicrobio.2010.06.019. PMID 20846810.
  2. 2.0 2.1 2.2 2.3 Calonge N, U.S. Preventive Services Task Force (2004). "Screening for syphilis infection: recommendation statement". Ann Fam Med. 2 (4): 362–5. PMC 1466700. PMID 15335137.

Template:WH Template:WS